Patent SG-11201806515R-A (SG)
Title: Eribulin-based antibody-drug conjugates and methods of use
Inventor: ALBONE EARL
IPC: A61K47/68
Filed: 2017-03-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 8 September 2017 (08.09.2017) WIPO I PCT (10) International Publication Number WO 2017/151979 Al 1111111111111101110111111111110101111101110111111110111111011111110111111111110111111 (51) International Patent Classification: A61K 47/68 (2017.01) (21) International Application Number: PCT/US2017/020529 (22) International Filing Date: 2 March 2017 (02.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/302,562 2 March 2016 (02.03.2016) US (71) Applicants: EISAI INC. [US/US]; 4 Corporate Drive, An- dover, MA 01810 (US). EISAI CO., LTD [JP/JP]; 6-10 Koishikawa, 4-chome, Bunkyo-ku, 112-8088 (JP). MORPHOTEK, INC. [US/US]; 210 Welsh Pool Road, Exton, PA 19341 (US). (72) Inventors: ALBONE, Earl, F.; 2105 Whitpain Hills, Blue Bell, PA 19422 (US). CHENG, Xin; 373 Saybrook Lane, Wallingford, PA 19086 (US). CUSTAR, Daniel, W.; 105 Peachtree Lane, North Andover, MA 01845 (US). FUR- UUCHI, Keiji; 1219 West Wynnewood Road, Unit 101, Wynnewood, PA 19096 (US). LI, Jing; 40 Lindoln Circle East, Andover, MA 01810 (US). MAJUMDER, Utpal; 137 High Plain Road, Andover, MA 01810 (US). UENAKA, Toshimitsu; 890 S. Matlack Street, #333, West Chester, PA 19382 (US). (74) Agents: MCDONELL, Leslie, A. et al.; Finnegan, Hende- rson, Farabow, Garrett & Dunner, LLP, 901 New York Av- enue, NW, Washington, DC 20001 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) W O 20 17 / 15 197 9 Al (54) Title: ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE (57) : Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.